Advanced bioanalytics for precision medicine

AbstractPrecision medicine is a new paradigm that combines diagnostic, imaging, and analytical tools to produce accurate diagnoses and therapeutic interventions tailored to the individual patient. This approach stands in contrast to the traditional “one size fits all” concept, according to which researchers develop disease treatments and preventions for an “average” patient without considering individual differences. The “one size fits all” concept has led to many ineffective or inappropriate treatments, especially for pathologies such as Alzheimer’s disease and cancer. Now, precision medicine is receiving massive funding in many countries, thanks to its social and economic potential in terms of improved disease prevention, diagnosis, and therapy. Bioanalytical chemistry is critical to precision medicine. This is because identifying an appropriate tailored therapy requires researchers to collect and analyze information on each patient’s specific molecular biomarkers (e.g., proteins, nucleic acids, and metabolites). In other words, precision diagnostics is not possible without precise bioanalytical chemistry. This Trend article highlights some of the most recent advances, including massive analysis of multilayer omics, and new imaging technique applications suitable for implementing precision medicine. Graphical abstractPrecision medicine combines bioanalytical chemistry, molecular diagnostics, and imaging tools for performing accurate diagnoses and selecting optimal therapies for each patient.

[1]  Daniel Filippini,et al.  Towards autonomous lab-on-a-chip devices for cell phone biosensing. , 2016, Biosensors & bioelectronics.

[2]  R. Williams,et al.  Biochemical Individuality: The Basis for the Genetotrophic Concept , 1957 .

[3]  최영식,et al.  [핵심 광 기술소개] MALDI(Matrix - Assisted Laser Desorption / Ionization) 질량분석법 , 2005 .

[4]  Joerg M. Buescher,et al.  Integration of omics: more than the sum of its parts , 2016, Cancer & Metabolism.

[5]  Irene van den Broek,et al.  Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  Jorge Ripoll,et al.  Advances in optical imaging for pharmacological studies , 2015, Front. Pharmacol..

[7]  A. Ganser,et al.  Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation , 2013, Leukemia.

[8]  L. Hood,et al.  Predictive, personalized, preventive, participatory (P4) cancer medicine , 2011, Nature Reviews Clinical Oncology.

[9]  M. Weale,et al.  Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? , 2016, The Pharmacogenomics Journal.

[10]  Paola Taroni,et al.  Review of optical breast imaging and spectroscopy , 2016, Journal of biomedical optics.

[11]  I. Y. Chen,et al.  Induced pluripotent stem cells: at the heart of cardiovascular precision medicine , 2016, Nature Reviews Cardiology.

[12]  Xueyang Feng,et al.  OM-FBA: Integrate Transcriptomics Data with Flux Balance Analysis to Decipher the Cell Metabolism , 2016, PloS one.

[13]  U. Sunar,et al.  Optical imaging of tissue obtained by transbronchial biopsies of peripheral lung lesions. , 2017, Journal of thoracic disease.

[14]  Yun Zhou,et al.  Quantitative multimodal multiparametric imaging in Alzheimer’s disease , 2016, Brain Informatics.

[15]  Robert Powers,et al.  Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics. , 2017, Progress in nuclear magnetic resonance spectroscopy.

[16]  Midhir J Patel,et al.  Role of Imaging in the Era of Precision Medicine. , 2017, Academic radiology.

[17]  F. Kiessling,et al.  Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects. , 2015, Chemical reviews.

[18]  M. E. Patterson,et al.  A Focus Group Exploration of Automated Case-Finders to Identify High-Risk Heart Failure Patients Within an Urban Safety Net Hospital , 2016, EGEMS.

[19]  David E. Fisher,et al.  Precision medicine for cancer with next-generation functional diagnostics , 2015, Nature Reviews Cancer.

[20]  C. Berking,et al.  The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of nonpigmented basal cell carcinoma: an observational study , 2015, The British journal of dermatology.

[21]  Christa M Cobbaert,et al.  Prospective applications of ultrahigh resolution proteomics in clinical mass spectrometry , 2016, Expert review of proteomics.

[22]  B. Turner,et al.  Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward “precision” cancer therapy , 2015, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[23]  J. Leppert,et al.  Perspective: Beyond the genome , 2016, Nature.

[24]  Jacqueline A. Hall,et al.  Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[25]  ping wang,et al.  Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer , 2017, Oncotarget.

[26]  Tassaneewan Laksanasopin,et al.  Point-of-Care Diagnostics: Recent Developments in a Connected Age. , 2017, Analytical chemistry.

[27]  Aydogan Ozcan,et al.  Mobile Phone-Based Microscopy, Sensing, and Diagnostics , 2016, IEEE Journal of Selected Topics in Quantum Electronics.

[28]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[29]  M. Karas,et al.  Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. , 1988, Analytical chemistry.

[30]  K. Kelnar,et al.  Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer. , 2017, Lung cancer.

[31]  Tang Tang,et al.  Nanoparticle-based multimodal PET/MRI probes. , 2015, Nanomedicine.

[32]  Carmen C. Y. Poon,et al.  Big Data for Health , 2015, IEEE Journal of Biomedical and Health Informatics.

[33]  Benjamin Balluff,et al.  Mass spectrometry imaging for clinical research - latest developments, applications, and current limitations. , 2017, The Analyst.

[34]  A. Merkoçi,et al.  Mobile phone-based biosensing: An emerging "diagnostic and communication" technology. , 2017, Biosensors & bioelectronics.

[35]  L. Pantanowitz,et al.  The role of informatics in patient‐centered care and personalized medicine , 2017, Cancer cytopathology.

[36]  Chao Zhang,et al.  Applications of Mass Spectrometry Imaging to Cancer. , 2017, Advances in cancer research.

[37]  C. Printz Neurotoxicity more likely in Hispanic children treated for acute lymphoblastic leukemia , 2019, Cancer.

[38]  Thomas E. Yankeelov,et al.  Quantitative multimodality imaging in cancer research and therapy , 2014, Nature Reviews Clinical Oncology.

[39]  R. Kittles,et al.  Warfarin Pharmacogenomics in Diverse Populations , 2017, Pharmacotherapy.

[40]  D. Mankoff,et al.  Making Molecular Imaging a Clinical Tool for Precision Oncology: A Review , 2017, JAMA oncology.

[41]  D. Wishart Emerging applications of metabolomics in drug discovery and precision medicine , 2016, Nature Reviews Drug Discovery.

[42]  H. Cui,et al.  Functional nanoparticles for magnetic resonance imaging. , 2016, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[43]  Gehua Wang,et al.  Recent development of mass spectrometry and proteomics applications in identification and typing of bacteria , 2016, Proteomics. Clinical applications.

[44]  Kate Grieve,et al.  Assessment of Sentinel Node Biopsies With Full-Field Optical Coherence Tomography , 2016, Technology in cancer research & treatment.

[45]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[46]  M. Mann,et al.  Electrospray Ionization for Mass Spectrometry of Large Biomolecules , 1990 .

[47]  T. Duarte,et al.  Personalized Proteomics: The Future of Precision Medicine , 2016, Proteomes.

[48]  M. Hutz,et al.  Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease. , 2016, Pharmacogenomics.

[49]  F. Ghiringhelli,et al.  Precision medicine in breast cancer: reality or utopia? , 2017, Journal of Translational Medicine.

[50]  Martin Wiedmann,et al.  Precision food safety: A systems approach to food safety facilitated by genomics tools , 2017 .

[51]  Bruno Domon,et al.  Advances in high‐resolution accurate mass spectrometry application to targeted proteomics , 2015, Proteomics.

[52]  Karl Garsha,et al.  Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[53]  Davide Prandi,et al.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.

[54]  T. Yogo,et al.  Relaxometric property of organosilica nanoparticles internally functionalized with iron oxide and fluorescent dye for multimodal imaging. , 2017, Journal of colloid and interface science.

[55]  A. Berry Analytic inquiry: Validation and practical considerations , 2017, Cancer cytopathology.

[56]  H. Ryu,et al.  Reconstruction of pathway modification induced by nicotinamide using multi-omic network analyses in triple negative breast cancer , 2017, Scientific Reports.

[57]  Shuzhao Li,et al.  Blood transcriptomics and metabolomics for personalized medicine , 2015, Computational and structural biotechnology journal.

[58]  William B. Bean,et al.  Biochemical Individuality: The Basis for the Genetotrophic Concept. , 1957 .

[59]  D. Shin,et al.  The medicinal chemistry of theragnostics, multimodality imaging and applications of nanotechnology in cancer. , 2010, Current topics in medicinal chemistry.

[60]  Alfonso Valencia,et al.  Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment , 2014, Clinical Cancer Research.

[61]  M O Karlsson,et al.  Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium , 2017, Clinical pharmacology and therapeutics.

[62]  Aldo Roda,et al.  Smartphone-based biosensors: A critical review and perspectives , 2016 .

[63]  Roberto Rey-Dios,et al.  Intraoperative fluorescence-guided resection of high-grade gliomas: a comparison of the present techniques and evolution of future strategies. , 2014, World neurosurgery.

[64]  Karen Y He,et al.  Big Data Analytics for Genomic Medicine , 2017, International journal of molecular sciences.

[65]  S. Basu,et al.  Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management? , 2016, Cancer biotherapy & radiopharmaceuticals.